For women : ERPF= 673,3 - (2.92*years of age) For men: ERPF = 854,2-(5.4*years of age)
The ERPF values were expressed as ml/min/1.73 [m.sup.2] and variations in the ERPF values compared to reference values (expected values for the sex and age) were given as ml/min and percentage.
A significant change (improvement) in ERPF after administration of ACE inhibitors was recorded in 55% of the subjects with diffuse renal parenchymal disease, whereas ERPF did not change significantly in 45% of them (Graph 1).
ACE inhibitors are widely used to treat various hypertensive conditions and in addition to lowering hypertension, these drugs affect the local renal hemodynamic conditions, thereby affecting GFR and ERPF. A number of clinical studies on the role of ACE inhibitors in decelerating the progression of renal disease have been published, and among the first were those conducted by the Melbourne Diabetic Nephropathy Study Group, the ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group, and the North American Microalbuminuria Group.
Our results in the subjects with essential hypertension, i.e., significantly increased ERPF and decreased systolic and diastolic pressures, also corroborate the significant role of ACE inhibitors in the protection of renal function in these subjects.
Likewise, in our study ERPF changes after ACE inhibition differed between the subjects with preserved renal function and those with reduced ERPF.
Abbreviations ACE --angiotensin converting enzyme GFR --glomerular filtration rate ERPF --effective renal plasma flow CrCl --creatinine celarance Rad je primljen 24.